Open Access Open Access  Restricted Access Subscription or Fee Access

Advancement of Poly-(ADP – Ribose) Polymerase (PARP) Inhibitors in Cancer Progression and Treatment

Neelima Chaudhary, Imteyaz Qamar

Abstract


DNA repair mechanisms are the most common and potential targets in cancer treatment. PARP enzymes play a crucial role in detection of DNA damage and its repair and also in apoptosis. Detailed knowledge of these mechanisms leads to the development of poly-(ADP-Ribose) polymerase (PARP) inhibitors as vigorous anticancer drugs with specific action. PARP inhibitors can selectivity kill tumours with deficiencies in DNA repair proteins like BRCA1/2, exploiting synthetic lethality concept. Some recent works show synergistic effect of PARP inhibitor with some DNA damaging agents, used for conventional therapeutics. In this review article, we will be discussing about PARP enzyme family specially PARP-1, their structure and working, along with brief introduction of DNA damage and repair. We will also discuss about PARP inhibition and its effect on tumour cells and clinical development of PARP inhibitors, either singly or in combination with other chemotherapeutics.

Keywords


PARP enzymes, cancer, PARP inhibitors, anticancer drug

Full Text:

PDF

References


O’Brien PJ. Catalytic Promiscuity and the Divergent Evolution of DNA Repair Enzymes. Chem. Rev. 2006; 106 (2):720–52p. [Pub Med: 16464022]

Gudmundsdottir K, Ashworth A. The Roles of BRCA1 and BRCA2 and associated Proteins in the Maintenance of Genomic Stability. Oncogene. 2006; 25(43):5864–74p. [Pub Med: 16998501]

Hottiger MO, Hassa PO, Luscher B, et al. Toward a Unified Nomenclature for Mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010; 35 (4):208–19p.doi:10.1016/j.tibs.2009.12.003.

Steffen JD, Pascal JM. New Players to the Field of ADP-Ribosylation Make the Final Cut. EMBO J. 2013; 32 (9):1205–7p.doi:10.1038/emboj.2013.83.

Dantzer F, Schreiber V, Niedergang C, et al. Involvement of Poly-(ADP ribose) Polymerase in Base Excision Repair. Biochimie. 1999; 81 (1–2):69–75p. [Pub Med: 10214912]

W.-M. Tong, U. Cortes, Z.-Q. Wang. Poly-(ADP-ribose) Polymerase: A Guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta. 2001; 1552(1): 27–37p.

Fortini P, Pascucci B, Parlatini E, et al. The base excision repair: mechanisms and its relevance for cancer susceptibility. Biochimie. 2003; 85 (11):1053–71p. [Pub Med: 14726013].

Hochegger H, Dejsuphong D, Fukushima T, et al. Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J. 2006; 25 (6):1305–14p. [PubMed: 16498404].

Steffen JD, Brody JR, Armen RS, Pascal JM. Structural Implications for Selective Targeting of PARPs. Front Oncol. 2013; 3:301. doi:10.3389/fonc.2013.00301.

Sugo N, Niimi N, Aratani Y, et al. Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase β-deficient mice. Biochem Biophys Res Commun. 2007; 354(3):656–61p.

Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly-(ADP-ribose) polymerase. Nature. 2005; 434(7035):913–17p. [PubMed: 15829966]

Dobzhansky T. Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila pseudoobscura. Genetics. 1946; 31 (3):269–90p.

Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly-(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA. 2011; 108(8):3406–11p.

Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006; 25:5846–53p. [PubMed: 16998499]

Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10 (4): 293-301p.

Wang L, Mason KA, Ang KK, et al. MK- 4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012; 30(6):2113-20p.

Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005; 7(4):1–20p. [PubMed: 15836799]

McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly-(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109–15p. [PubMed: 16912188]

Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010; 28(22):3555–61p.

Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCAdeficient advanced breast cancer. J Clin Oncol (Meeting Abstracts). 2009; 27(18S):CRA501.

Fong PC, Boss DS, Yap TA, et al. Inhibition of poly-(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123–34p. [PubMed: 19553641]

Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. (Meeting Abstracts) 2009; 27(15S):5500.

Giaccone G, Rajan A, Kelly RJ, et al. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. J Clin Oncol. 2010; 28:15s. (suppl; abstr 3027).

Lee J, Annunziata CM, Minasian LM, et al. Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). J Clin Oncol. 2011; 29 (suppl; abstr 2520).

Liu J, Fleming GF, Tolaney SM, et al. A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011; 29 (suppl; abstr 5028).

Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2Hindazole-7-carboxamide (MK-4827): a novel oral poly-(ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009; 52(22):7170–85p. [PubMed: 19873981]

Schelman WR, Sandhu SK, Moreno Garcia V, et al. First-in-human trial of a poly- (ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). J Clin Oncol. 2011; 29 (suppl; abstr 3102).

Sandhu SK, Schelman WR, Wilding G, et al. The poly-(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14(9):882-92p.

Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly- (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009; 27(16):2705–11p. [PubMed: 19364967]

LoRusso P, Ji JJ, Li J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly-(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solidtumors. J Clin Oncol. 2011; 29 (suppl; abstr 3000).

Tan AR, Toppmeyer D, Stein MN, et al. Phase I trial of veliparib, (ABT-888), a poly-(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. J ClinOncol. 2011; 29 (suppl; abstr 3041).

Pishvaian MJ, Slack R, Witkiewicz A, et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pre-treated, metastatic colorectal cancer. J Clin Oncol. 2011; 29 (suppl; abstr 3502).

Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010; 28:15s. (suppl;abstr 1019)

Viswanathan S, Wesolowski R, Layman RM, et al. A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). J Clin Oncol. 2011; 29 (suppl; abstr TPS106).

Thomas HD, Calabrese CR, Batey MA, et al. Preclinical selection of a novel poly- (ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer

Ther. 2007; 6:945–56p. [PubMed: 17363489]

Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly-(ADPribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol. 2006; 24 (suppl; abstr 8013).

Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly-(ADPribose) polymerase inhibitor AG-014699. Br J Cancer. 2010; 103(10):1588–96p. [PubMed: 20978505]

Ali M, Telfer BA, McCrudden C, et al. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly-(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res. 2009; 15(19):6106–12. [PubMed: 19789326]

Hunter JE, Willmore E, Irving JA, et al. NF-κB mediates radio-sensitization by the PARP- inhibitor, AG-014699. Oncogene. 2012; 31(2): 251-64p.

Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008; 451:1111–5p. [PubMed: 18264088]

Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008; 451:1116–20p. [PubMed: 18264087]

Swisher E, Sakai W, Karlan B, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008; 68:2581–6p. [PubMed: 18413725]


Refbacks

  • There are currently no refbacks.